Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
-3.93% $2.93
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 17.00 mill |
EPS: | -0.680 |
P/E: | -4.31 |
Earnings Date: | Apr 02, 2024 |
SharesOutstanding: | 5.80 mill |
Avg Daily Volume: | 0.0131 mill |
RATING 2024-03-28 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -4.31 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.23x |
Company: PE -4.31 | industry: PE 18.71 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.662 (-122.59%) $-3.59 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 2.74 - 3.12 ( +/- 6.42%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-22 | Mehalik Daniella | Buy | 70 000 | Stock Option (Right to Buy) |
2024-01-22 | Mehalik Daniella | Buy | 35 000 | Stock Option (Right to Buy) |
2023-11-27 | Mehalik Daniella | Sell | 0 | Common Stock, $.005 Par Value |
2023-09-21 | Shoemaker Shannon | Buy | 80 000 | Stock Option (Right to Buy) |
2023-09-21 | Shoemaker Shannon | Buy | 40 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
94.00 |
Last 96 transactions |
Buy: 1 000 549 | Sell: 33 710 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.93 (-3.93% ) |
Volume | 0.0142 mill |
Avg. Vol. | 0.0131 mill |
% of Avg. Vol | 108.39 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.